Biomarker-guided treatment for endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a suspected or confirmed endometrial cancer (cancer of the womb)
- You are 18 years or older
- You can have surgery or surgical treatment for your endometrial cancer
- Your care plan includes weekly paclitaxel treatment for your cancer
- A new tumor tissue biopsy is possible so the team can test stathmin levels
- You can and will sign consent (including being able to communicate despite language barriers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a weekly dose of the chemotherapy drug paclitaxel to standard treatment helps women with advanced or recurrent endometrial cancer. It is for patients whose cancer has returned or not responded to prior therapy, including at least one platinum-based chemotherapy and an immune checkpoint inhibitor.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study is testing whether a special kind of medicine called a PARP inhibitor can work against endometrial cancer cells grown in a lab from your tumor. The goal is to find out which patients might benefit from this treatment in the future.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.